WALTHAM, Mass • 2023-04-03

BostonGene Highlights Comprehensive Approach to Precision Medicine at hubXchange’s East Coast Genomics in Precision Oncology 2023

5 min to read

BostonGene announced today that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts
WALTHAM, Mass, April 3, 2023

BostonGene announced today that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts. The event brings together executives from pharma and biotech to address and find solutions to the key issues that currently need to be addressed in genomics-led oncology precision medicine strategies.

Presentation details:



Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure

  • Wednesday, April 5 | 1:20 PM ET

  • Speaker: Alexander Bagaev, PhD, VP, Product Development, BostonGene


This session will highlight BostonGene’s comprehensive profile of a patient’s disease for therapy selection and stratification for IO clinical trials to improve outcomes by using CLIA-certified advanced whole exome and whole transcriptome sequencing paired with deep immunoprofiling and best-in-class analytics.

"I am excited to participate in the East Coast Genomics in Precision Oncology 2023 and to present how BostonGene’s transcriptional profiling and advanced analytics can reveal detailed characteristics of functional immune programs in the tumor microenvironment.,” said Alexander Bagaev, PhD, VP, Product Development at BostonGene. “Our comprehensive molecular profiling approach and innovative bioinformatics platform stratifies patients based on IO response and identifies the most effective therapy, ultimately improving patient outcomes.”

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com